Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study

BACKGROUND: The rechallenge of immune checkpoint inhibitors (ICI) is now an optional strategy for patients who discontinued ICI due to immune-related adverse events (irAEs) or disease progression. However, little data is available for the prognosis and prognostic factors of patients receiving ICI re...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jin, Zeng, Ran, Zhou, Jianping, Luo, Lifeng, Lyu, Mengchen, Liu, Fang, Sun, Xianwen, Zhou, Ling, Wang, Xiaofei, Bao, Zhiyao, Chen, Wei, Dumoulin, Daphne W., Gao, Beili, Xiang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271445/
https://www.ncbi.nlm.nih.gov/pubmed/35832441
http://dx.doi.org/10.21037/tlcr-22-360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271445/
https://www.ncbi.nlm.nih.gov/pubmed/35832441
http://dx.doi.org/10.21037/tlcr-22-360

Ejemplares similares